Is Buying Johnson & Johnson (JNJ) Here a Winning Strategy?

Ajustar Comentario Impresión

Johnson & Johnson now has $348.35B valuation. The stock increased 1.01% or $1.3 during the last trading session, reaching $130.08. About 2.45 million shares traded.

Shares of Johnson & Johnson (NYSE:JNJ) opened at 128.78 on Friday. It has underperformed by 4.16% the S&P500. United American Securities Inc acquired 3,290 shares as Johnson & Johnson Com (JNJ)'s stock rose 6.85%. The firm has a market capitalization of $350.41 billion, a PE ratio of 21.87 and a beta of 0.74. About 485,632 shares traded. After a recent check, Johnson & Johnson (NYSE:JNJ)'s 14-day RSI is presently at 69.38. It has underperformed by 5.82% the S&P500. Out of 15 Wall Street analysts rating Johnson & Johnson, 7 give it "Buy", 1 "Sell" rating, while 7 recommend "Hold".

Ratings analysis reveals 47% of Johnson & Johnson's analysts are positive. The firm has "Buy" rating by Argus Research given on Wednesday, April 20. The firm earned "Buy" rating on Thursday, May 25 by Jefferies. The company now has an average rating of "Hold" and a consensus price target of $130.90. The rating was initiated by UBS on Tuesday, September 22 with "Buy". The stock of Johnson & Johnson (NYSE:JNJ) earned "Outperform" rating by RBC Capital Markets on Wednesday, January 25. Finally, Cowen and Company reiterated a "buy" rating and set a $143.00 price objective (up from $138.00) on shares of Johnson & Johnson in a report on Friday, May 19th. The stock of Johnson & Johnson (NYSE:JNJ) has "Hold" rating given on Tuesday, June 14 by Jefferies. Barclays PLC reiterated an "equal weight" rating and set a $130.00 target price (up from $125.00) on shares of Johnson & Johnson in a research report on Monday, April 17th.

Community Bank, which manages about $456.05 million US Long portfolio, decreased its stake in Spdr Tech Select Sector Etf (XLK) by 7,500 shares to 7,219 shares, valued at $349,000 in 2016Q4, according to the filing. Itau Unibanco Holding S.A. purchased a new stake in shares of Johnson & Johnson during the third quarter valued at about $104,000.

Since February 1, 2017, it had 0 insider buys, and 5 selling transactions for $14.98 million activity.

COPYRIGHT VIOLATION WARNING: "Johnson & Johnson (JNJ) Shares Sold by Charter Trust Co." was published by Transcript Daily and is owned by of Transcript Daily. $2.50 million worth of AbbVie Inc (NYSE:ABBV) was sold by CHASE WILLIAM J on Thursday, May 18.

Investors sentiment increased to 0.94 in Q4 2016. Its down 0.05, from 1.03 in 2016Q3. It improved, as 63 investors sold JNJ shares while 834 reduced holdings. Advocacy Wealth Management Services LLC raised its position in Johnson & Johnson by 62.8% in the first quarter.

Several equities research analysts recently issued reports on JNJ shares. Mckinley Carter Wealth Ser reported 7,016 shares. Nomura Asset Mngmt reported 1.84% stake. Jensen has 4.54% invested in Johnson & Johnson (NYSE:JNJ). Bartlett And Communications Limited Liability Corporation reported 0.42% in AbbVie Inc (NYSE:ABBV). Mason Street Advsr Lc holds 372,156 shares or 1.16% of its portfolio. Morgan Stanley reported 13.07M shares.

Amici Capital Llc holds 4.04% of its portfolio in Independence Holding Company for 531,107 shares.

More notable recent Johnson & Johnson (NYSE:JNJ) news were published by: which released: "The Definitive Guide to Johnson & Johnson Stock Dividends" on June 02, 2017, also with their article: "Johnson & Johnson Faces FDA Headwind" published on May 17, 2017, published: "Johnson & Johnson offers European Union concessions over Actelion deal" on May 18, 2017. Confluence Mngmt Ltd Co stated it has 912,580 shares or 2.55% of all its holdings. Arkansas-based Garrison Financial Corporation has invested 2.3% in Johnson & Johnson (NYSE:JNJ). Moreover, Accredited Investors Inc. has 0.11% invested in the company for 21,236 shares. Huntington National Bank boosted its stake in Johnson & Johnson by 39.5% in the third quarter. Goldman Sachs upgraded Johnson & Johnson (NYSE:JNJ) rating on Monday, March 14. One Capital Ltd Liability stated it has 0.92% of its portfolio in Johnson & Johnson (NYSE:JNJ).

More notable recent Johnson & Johnson (NYSE:JNJ) news were published by: which released: "Illinois, other states settle with Johnson & Johnson for $33 million" on May 24, 2017, also with their article: "Johnson & Johnson offers European Union concessions over Actelion deal" published on May 18, 2017, published: "Johnson & Johnson Faces FDA Headwind" on May 17, 2017.

Analysts await Genesee & Wyoming Inc (NYSE:GWR) to report earnings on August, 7. They expect $1.78 EPS, up 2.30 % or $0.04 from last year's $1.74 per share. JNJ's profit will be $4.81B for 18.09 P/E if the $1.78 EPS becomes a reality. After posting $1.83 EPS for the previous quarter, Johnson & Johnson's analysts now forecast -2.73 % negative EPS growth.

More notable recent Genesee & Wyoming Inc (NYSE:GWR) news were published by: which released: "Genesee & Wyoming Completes Acquisition of Heart of Georgia Railroad" on May 31, 2017, also with their article: "BRIEF-Genesee & Wyoming appoints John Hellmann as chairman" published on May 26, 2017, published: "Will Genesee & Wyoming's Buying Spree Continue?" on March 13, 2017. Popular Inc. Cmn (NASDAQ:BPOP) was raised too. The insider Walsh Matthew O. sold $269,318. Paradigm Inc owns 73,900 shares for 0.83% of their portfolio. The stock of AbbVie Inc (NYSE:ABBV) has "Sell" rating given on Wednesday, April 6 by Societe Generale. On Tuesday, February 28 the insider Kapusta Ronald A sold $1.78 million. It also reduced State Str Corp (NYSE:STT) stake by 16,178 shares and now owns 16,300 shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.